Black Diamond Therapeutics, Inc.

NASDAQ: BDTX · Healthcare · Biotechnology

PublicHQ Cambridge, MA · MiddlesexCIK 0001701541Reports USD

#388 of 1,394 Healthcare companies by revenue

EA Score

60C

FH 73DQ 45GM —SS 46

v0.1 · 55/100 weight · provisional

↑ net margin, return on assets · ↓ Piotroski F, disclosure history

Methodology →

Revenue TTM

Rev growth YoY (TTM)

-100.0%

Net income (FY)

$22.4M

Employees

Market cap

$115.2M

Financials — latest annual

SEC EDGAR · USD-normalized

ConceptUSDNativeFY

Revenue$70.0M$70.0M2025

Net income$22.4M$22.4M2025

Operating income$12.5M$12.5M2025

Total assets$143.0M$143.0M2025

Liabilities$30.8M$30.8M2025

Equity$112.2M$112.2M2025

Revenue trend

FY2019 – FY2025 · USD

FY19

FY20

FY25

$70.0M

FY25

Revenue by segment

Filed disclosures · FY2025

By product

Reportable100%

By geography

Not disclosed.

The read

Black Diamond Therapeutics, Inc. booked $70.0M in FY2025 revenue — among the slowest-growing Healthcare companies we track, at a 32.0% net margin.

Peers · Healthcare

Grown Rogue International Inc.52D Medexus Pharmaceuticals Inc.64C Harbor Diversified, Inc.——Corbus Pharmaceuticals Holdings, Inc.44D

Neighbors

Middlesex →

GE Vernova Inc.$38.1B63C Thermo Fisher Scientific Inc.$44.6B86A Analog Devices, Inc.$11.0B87A The TJX Companies, Inc.$60.4B85A Boston Scientific Corporation$20.1B88A Alnylam Pharmaceuticals, Inc.$3.7B79B+

Key facts

CEOMark A. Velleca

SectorHealthcare

IndustryBiotechnology

HeadquartersCambridge, MA

ExchangeNASDAQ: BDTX

Employees24

IPO date2020-01-31

Latest filings

8-K2026-06-29 8-K2026-05-21 10-Q2026-05-07 8-K2026-05-07 DEF 14A2026-04-29 8-K2026-03-16 10-K2026-03-16 8-K2025-12-03

Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.